4 ms·
There is a large domestic market, and also a potential global market of COVAX initiative members. If it can successfully compete against the Oxford-AstraZeneca/
by joshuaissac 5y ago
There is a large domestic market, and also a potential global market of COVAX initiative members. If it can successfully compete against the Oxford-AstraZeneca/Covishield vaccine on price, then gaining acceptance should not be a problem.
The kind of people who would balk at a DNA vaccine would probably also reject other types of vaccine, so the underlying technology is not that important to that aspect.
- yyyk 5y agoUpvoted. I don't agree, but you make a reasonable argument and I don't think you should be downvoted. Back to the issue, even poor states have more considerations than price. First, they want effective vaccines. That means they need to be approved/adopted by some influential states, since poor states don't have widely trusted FDAs. Second, even poor states have antivax (we can blame whatsapp and facebook for this). The people in charge of imports must want to make sure the vaccine is accepted, which points us at the same direction (they want to be able to say 'even big state like X uses this vaccine!' and avoid 'scary' new tech). The West has mRNA and won't want to have even more antivax due to scary name. Russia/China seem uninterested in the tech. That leaves us with India, which is a large enough market for the manufacturer (Zydus Cadila) to make profit, but alas is not wealthy or influential enough to win worldwide acceptance by itself. Summary: I don't think new tech can be pushed via COVAX alone when there are alternatives, even if it wins on price (which is far from assured).